血小板膜糖蛋白GPIb受体拮抗剂的研究进展

Research Progress in Inhibitor of GlycoproteinIb Receptor on Platelets

血小板膜糖蛋白GPIb受体与血管性血友因子（vWF）相互作用是血小板在血管损伤部位发生黏附和动脉血栓形成的始动环节，同时也是高剪切力下血小板在血管病理性狭窄部位发生黏附和聚集的重要机制，因此，GPIb受体被认为是抗血栓治疗的重要靶点。GPIb受体拮抗剂通过阻GPIb复合物与vWF相互作用而抑制血小板黏附和聚集，达到抗血小板血栓形成的目的，对于心、脑血管疾病防治有着重要的意义。本文综述当前一些GPIb受体拮抗剂研究进展，将要探讨的有：684-Fab、SZ2，属于抗GPIbα鼠源单克隆抗体；RAM．1，属于抗GPIbβ的鼠源单克隆抗体；Agkisacucetin、Jerdonibitin、Rhodocetin—αβ，均属蛇毒蛋白。

The interaction between the platelet receptor glycoprotein （GP） Ib - IX - V complex and yon Willebrand factor （VWF） plays a key role in initiation of platelet adhesion and arterial thrombus formation at the sites of vascular injury and it＇ s also plays an important role in the pathogenesis of platelet adhesion and aggregation under high shear stress conditionsat at the site of pathological hemadostenosis. Therefore GPIb has been suggested as a desirable antithrombotic target. GPIb inhibitors can prevent the formation of thrombus by inhibiting the GPIb - vWF interaction and subsequently platelet adhesion or aggregation. And it has important implication for prevention and treatment of cardiovascular and cerebrovascular diseases. This paper discusses that 6B4 - Fab and SZ2 which are both murine monoclonal antibody targeting the GPIbα ; RAM. 1, a murine monoclonal antibody against GPIbβ ; Agkisacucetin, Jerdonibitin and Rbodocetin - αβ which all belong to snaclecs.